Does Tufts Health Plan Cover Eliquis?

Tufts Health Plan Formulary Placement for Eliquis

Tufts Health Plan includes Eliquis on formularies across most of its product lines, though the specific tier varies by plan type and year. Commercial HMO and PPO plans typically list Eliquis as a Tier 2 preferred brand or Tier 3 non-preferred brand drug.

Tier placement determines your out-of-pocket cost. On Tufts commercial plans, Tier 2 copays commonly fall between $30 and $60 for a 30-day supply, while Tier 3 placement may push costs to $60 to $90 or a 25% to 33% coinsurance. Tufts Medicare Advantage plans often place Eliquis on their Part D formulary with similar tiering, though Medicare members benefit from the Inflation Reduction Act's $2,000 annual out-of-pocket cap on prescription drugs that took effect in 2025. This cap can significantly reduce annual Eliquis costs for Medicare enrollees who reach the coverage gap.

Tufts updates its formulary at least annually, and mid-year changes can shift tier placement. Members should verify current placement by logging into the Tufts Health Plan member portal or calling the number on the back of their insurance card. The FDA's prescribing information for Eliquis lists five approved indications, and coverage decisions often hinge on whether the prescribed use matches one of these labeled indications [1].

Understanding Prior Authorization Requirements

Some Tufts plans require prior authorization before dispensing Eliquis. This means your prescriber must submit clinical documentation showing the drug is medically necessary for your specific condition before the pharmacy can fill the prescription.

Prior authorization criteria at Tufts typically require documentation of a confirmed diagnosis (atrial fibrillation, deep vein thrombosis, or pulmonary embolism), evidence that the patient has no contraindications to apixaban, and in certain plans, proof that a less expensive anticoagulant was tried or considered. The turnaround for standard prior authorization is generally 48 to 72 hours, though urgent requests can be processed within 24 hours.

The American College of Cardiology and American Heart Association 2019 guidelines for management of atrial fibrillation recommend direct oral anticoagulants (DOACs) over warfarin as first-line therapy for most patients with nonvalvular atrial fibrillation. The guideline states: "DOACs are recommended over warfarin in DOAC-eligible patients with AF" [2]. This recommendation strengthens prior authorization requests because it establishes Eliquis as a guideline-concordant first-line option, not an alternative to warfarin. If your prescriber cites this guideline in the authorization request, approval rates tend to be higher.

Step therapy requirements on certain Tufts plans may ask that a patient try warfarin first. However, prescribers can often obtain a step therapy exception by documenting clinical reasons warfarin is inappropriate, such as difficulty maintaining INR in therapeutic range, drug-food interactions, or patient inability to attend regular INR monitoring appointments [3].

What the Clinical Evidence Says About Eliquis

Eliquis earned its formulary position through strong clinical trial data. Understanding this evidence helps if you need to appeal a coverage denial or justify the drug's value to your plan.

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to warfarin in patients with atrial fibrillation and at least one additional stroke risk factor. Apixaban reduced the rate of stroke or systemic embolism by 21% compared to warfarin (hazard ratio 0.79, 95% CI 0.66 to 0.95, P=0.01). Major bleeding was 31% lower with apixaban (HR 0.69, P<0.001), and all-cause mortality dropped by 11% (HR 0.89, P=0.047) [4]. These results established apixaban as the only DOAC to demonstrate superiority over warfarin across all three endpoints in a single trial.

For venous thromboembolism, the AMPLIFY trial (N=5,395) showed apixaban was noninferior to conventional therapy (enoxaparin followed by warfarin) for recurrent VTE, with significantly less major bleeding (0.6% vs. 1.8%, relative risk 0.31, P<0.001) [5]. The AMPLIFY-EXT trial then demonstrated that extended treatment with apixaban reduced recurrent VTE by 64% compared to placebo without a significant increase in major bleeding [6].

Dr. Christopher Granger, the principal investigator of ARISTOTLE at Duke University, noted: "Apixaban had a favorable benefit-risk profile compared with warfarin, with significant reductions in stroke, bleeding, and mortality." This profile is why major cardiology guidelines now position Eliquis as a preferred anticoagulant option.

Eliquis Cost Breakdown on Tufts Plans

The retail price of Eliquis without insurance averages approximately $600 to $650 for a 30-day supply of 5 mg twice daily. Insurance coverage through Tufts reduces this substantially, but out-of-pocket costs vary by plan design.

On Tufts commercial HMO plans, members with Tier 2 coverage typically pay $35 to $50 per fill. Tufts PPO and POS products may apply coinsurance instead of flat copays, resulting in costs of $75 to $150 before meeting the out-of-pocket maximum. Tufts Medicare Advantage plans follow Part D cost-sharing structures, where members in the initial coverage phase may pay 25% coinsurance after their deductible.

Bristol-Myers Squibb and Pfizer offer the Eliquis 360 Support copay card for commercially insured patients. Eligible members can reduce their copay to as low as $10 per month, with a maximum annual benefit. This card cannot be used by patients enrolled in Medicare, Medicaid, or other federal healthcare programs. Tufts members with commercial coverage should ask their pharmacist to apply the copay card at the point of sale.

For Tufts Medicare Advantage enrollees, the Medicare Part D coverage gap provisions provide additional cost relief. Since 2025, the $2,000 annual cap on out-of-pocket Part D spending means that even members taking Eliquis year-round will not exceed this threshold. Patient assistance programs from the manufacturer and independent foundations like the PAN Foundation may also help offset remaining costs.

Mail-order pharmacy through Tufts often provides a 90-day supply for the cost of two copays, which can reduce the per-month expense by roughly one-third compared to 30-day retail fills [7].

How to Appeal a Coverage Denial

If Tufts denies coverage for Eliquis, you have the right to appeal. Understanding the appeals process can help you obtain coverage for a medication your physician considers medically necessary.

Start by requesting the denial letter, which outlines the specific reason coverage was refused. Common denial reasons include missing prior authorization, step therapy requirements not being met, or the prescribed indication falling outside FDA-approved uses. Your prescriber should submit a first-level (internal) appeal within 60 days of the denial. The appeal letter should include the specific clinical rationale for Eliquis, relevant trial data (particularly ARISTOTLE for AF patients), documentation of any prior anticoagulant trials or contraindications, and the applicable guideline recommendation.

The Endocrine Society and American Heart Association clinical practice statements support DOAC use as first-line anticoagulation for qualifying patients [8]. Citing these in your appeal adds clinical weight. Dr. Elaine Hylek, professor of medicine at Boston University and a leading researcher in anticoagulation, has stated: "For most patients with atrial fibrillation, the clinical evidence clearly favors direct oral anticoagulants over warfarin as the initial choice."

If the internal appeal fails, Tufts members can request an external review by an independent third party. Massachusetts state law requires insurers to comply with independent external review decisions. For Medicare Advantage members, the appeals process follows CMS guidelines, which include reconsideration by the plan, review by an Independent Review Entity, and if necessary, escalation to an Administrative Law Judge for claims exceeding a set dollar threshold [9].

Eliquis vs. Other Anticoagulants on Tufts Formularies

Tufts Health Plan covers several anticoagulant options, and understanding how they compare can inform conversations with your prescriber about the best choice for your situation.

Warfarin (generic, Tier 1) remains the least expensive option, with copays often under $10 per month. It requires regular INR monitoring, dietary restrictions, and carries a higher bleeding risk profile in the ARISTOTLE comparison. Rivaroxaban (Xarelto) is also covered on most Tufts formularies, typically at a similar tier to Eliquis. The ROCKET AF trial (N=14,264) showed rivaroxaban was noninferior to warfarin for stroke prevention, but it did not achieve superiority for the primary endpoint on an intention-to-treat analysis [10]. Rivaroxaban is dosed once daily, which some patients prefer.

Edoxaban (Savaysa) sits on some Tufts formularies as a Tier 3 drug. The ENGAGE AF-TIMI 48 trial (N=21,105) demonstrated noninferiority to warfarin with lower bleeding rates, but edoxaban carries a boxed warning against use in patients with creatinine clearance greater than 95 mL/min due to reduced efficacy in that population [11].

Dabigatran (Pradaxa) is covered on most Tufts plans and was the first DOAC approved for atrial fibrillation based on the RE-LY trial. Unlike apixaban, dabigatran has a specific reversal agent (idarucizumab) and requires twice-daily dosing. Head-to-head network meta-analyses suggest apixaban has the most favorable bleeding profile among all four DOACs, particularly for gastrointestinal bleeding [12].

If cost is the primary barrier, discuss with your Tufts plan representative whether switching to a lower-tier anticoagulant with a comparable safety profile makes clinical sense for your condition.

Special Populations and Coverage Considerations

Coverage criteria for Eliquis on Tufts plans may differ for certain patient groups. Dose adjustments and indication-specific approvals affect both prescribing and insurance processing.

Patients who meet two or more of the following criteria receive a reduced dose of 2.5 mg twice daily: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or greater. This dosing distinction matters for coverage because the prior authorization criteria at Tufts often specify the approved dose based on these clinical parameters. An incorrect dose on the prescription can trigger a denial [13].

For post-surgical VTE prophylaxis after hip or knee replacement, Tufts typically covers Eliquis for 12 days (knee) or 35 days (hip), aligning with the FDA-approved duration in the prescribing label [1]. Requests extending beyond these durations may require additional clinical justification.

Cancer-associated thrombosis represents a growing but sometimes contested indication. The CARAVAGGIO trial (N=1,170) demonstrated apixaban was noninferior to dalteparin for recurrent VTE in cancer patients, without a significant increase in major bleeding (3.8% vs. 4.0%, P=0.60) [14]. Some Tufts plans have added cancer-associated VTE as a covered indication; others still require prior authorization with supporting documentation from the treating oncologist.

Patients transitioning from warfarin to Eliquis should coordinate with both their prescriber and pharmacy to avoid gaps in anticoagulation coverage. Tufts typically approves the transition without additional prior authorization if the member already has an active anticoagulation authorization on file.

Tufts MassHealth and ACO Plan Coverage

Tufts Health Plan administers MassHealth ACO plans in Massachusetts, and formulary coverage for Eliquis under these plans follows MassHealth Pharmacy Program guidelines rather than Tufts' commercial formulary.

MassHealth covers Eliquis with prior authorization for approved indications. The authorization process requires documentation of diagnosis, appropriate dosing, and confirmation that the prescriber has reviewed bleeding risk using a validated tool such as the HAS-BLED score. MassHealth generally does not impose step therapy requiring a warfarin trial first for patients with atrial fibrillation, aligning with AHA/ACC guideline recommendations [2].

MassHealth members pay no copay or a nominal copay (typically $1 to $3.65) for covered prescriptions, making Eliquis significantly more affordable under these plans compared to commercial Tufts products. Members receiving MassHealth through a Tufts ACO plan should contact Tufts Health Together or their assigned care coordinator for assistance with the prior authorization process.

Steps to Confirm Your Coverage Today

Call the Tufts member services number on your insurance card and ask three specific questions: Is Eliquis on my plan's formulary, and on which tier? Does my plan require prior authorization or step therapy for Eliquis? What is my estimated copay or coinsurance for a 30-day supply at my preferred pharmacy?

If your plan requires prior authorization, ask your prescribing physician to submit it proactively before sending the prescription to the pharmacy. Provide the pharmacy with your Eliquis copay card (if commercially insured) and request a 90-day mail-order fill to reduce per-month costs. For Medicare Advantage members, confirm whether you have reached the $2,000 annual Part D out-of-pocket cap, as this affects your cost-sharing for the remainder of the plan year.